A phase I clinical trial of targeted CEA-CAR-T cells for CRC treatment found that 7 of the 10 CEA+ patients were in stable condition after CAR-T cell treatment, with 2 patients maintaining this state for more than 30 weeks, and 2 patients underwent tumor regression (268). This evidence concerns the gene CEACAM5 and neoplasm.